Potential for dipeptidyl peptidase-4 inhibitor and sodium glucose cotransporter 2 inhibitor single-pill combinations

References

• Boehringer Ingelheim. Aggrenox (aspirin/extended-release dipyridamole) label. Available from: www.aggrenox.com/
   Google Scholar
• Borghi C, Cicero AF. Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril. Clin Drug Investig 2010;30(12):843-54
   PubMed Web of Science ®Google Scholar
• Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med 2014;371(3):248-59
   PubMed Web of Science ®Google Scholar
• Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27(6):1157-68
   PubMed Web of Science ®Google Scholar
• Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-49
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368(9548):1696-705
   PubMed Web of Science ®Google Scholar
• Hare KJ, Vilsboll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010;59(7):1765-70
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88(6):2719-25
   PubMed Web of Science ®Google Scholar
• Meier JJ, Kemmeries G, Holst JJ, et al. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005;54(7):2212-18
   PubMedGoogle Scholar
• Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101(3):515-20
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-31
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13(1):7-18
   PubMed Web of Science ®Google Scholar
• Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009;53(5):875-83
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14(1):5-14
   PubMed Web of Science ®Google Scholar
• Singh SK, Gupta AK. SGLT2 inhibitors for treatment of type 2 diabetes mellitus: focus on canagliflozin. Muller J Med Sci Res 2014;4:166-73
   Google Scholar
• Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012;8(8):495-502
   PubMed Web of Science ®Google Scholar
• Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453-67
   PubMedGoogle Scholar
• Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44(4):375-93
   PubMed Web of Science ®Google Scholar
• BI 10773 (Empagliflozin) cardiovascular outcome event trial in type 2 diabetes mellitus patients. Available from: http://clinicaltrials.gov/show/NCT01131676
   Google Scholar
• MARLINA - T2DM: efficacy, safety & modification of albuminuria in type 2 diabetes subjects with renal disease with Linagliptin. Available from: http://clinicaltrials.gov/ct2/show/NCT01792518?term=MARLINA&rank=1
   Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10(4):289-301
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124(2):499-508
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124(2):509-14
   PubMed Web of Science ®Google Scholar
• Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 2012;122(1):4-12
   PubMed Web of Science ®Google Scholar
• Edgerton DS, Johnson KM, Cherrington AD. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front Biosci (Landmark Ed) 2009;14:1169-81
   PubMedGoogle Scholar
• Muscelli E, Casolaro A, Gastaldelli A, et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012;97(8):2818-26
   PubMed Web of Science ®Google Scholar
• Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92(4):1249-55
   PubMed Web of Science ®Google Scholar
• Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89(5):2078-84
   PubMed Web of Science ®Google Scholar
• Brand T, Macha S, Mattheus M, et al. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv Ther 2012;29(10):889-99
   PubMed Web of Science ®Google Scholar
• Friedrich C, Metzmann K, Rose P, et al. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther 2013;35(1):A33-42
   PubMed Web of Science ®Google Scholar
• Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food. Available from: http://clinicaltrials.gov/show/NCT01189201
   Google Scholar
• Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13(1):47-54
   PubMed Web of Science ®Google Scholar
• Drug interaction study of saxagliptin in combination with dapagliflozin in healthy participants. Available from: http://clinicaltrials.gov/ct2/show/results/NCT01662999?sect=Xmledba970156
   Google Scholar
• Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med 2012;12(8):995-1004
   PubMed Web of Science ®Google Scholar
• Kern M, Kloting N, Glempler R, et al. A promising Combination for Future Treatment of Type 2 Diabetes: Coadministration of Empagliflozin (SGLT2 Inibitor) with Linagliptin (DPP-4 Inhibitor). Diabetes 2013;62(Suppl 1):A283
   PubMedGoogle Scholar
• Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013;19(6):1050-61
   PubMedGoogle Scholar
• Park H, Park C, Kim Y, et al. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann Pharmacother 2012;46(11):1453-69
   PubMedGoogle Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159(4):262-74
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 2013;166(2):217-23; e211
   PubMed Web of Science ®Google Scholar
• Wysham CH, Woo VC, Mathieu C, et al. Canagliflozin (CANA) added on to DPP-4 inhibitors or GLP-1 agonists with or without other antihyperglycemic agents in Type 2 Diabetes Mellitus. Diabetes 2013;62(Suppl 1):A279
   Google Scholar
• Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37(3):740-50
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in poorly controlled type 2 diabetes on metformin: randomized, double-blind trial of saxagliptin+dapagliflozin vs. saxagliptin and dapagliflozin alone. Diabetes 2014;63(Suppl 1A):LB32
   Google Scholar
• Lewin A, DeFronzo RA, Sanjay P, et al. Fixed dose combination of empagliflozin/linagliptin for 24 weeks in drug naïve patients with type 2 diabetes mellitus (T2DM). Diabetes 2014;63(Suppl 1A):LB33
   Google Scholar
• DeFronzo RA, Lewin A, Sanjay P, et al. Fixed dose combination of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with type 2 diabetes mellitus (T2DM). Diabetes 2014;63(Suppl 1A):LB33
   Google Scholar
• Lewin A, Defronzo R, Patel S, et al. Fixed dose combinations of empagliflozin and linagliptin for 52 weeks in drug naive patients with type 2 diabetes. Diabetologia 2014;57(Suppl 1):S346[851]
   Google Scholar
• Patel S, DeFronzo R, Lewin A. Fixed dose combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with type 2 diabetes. Diabetologia 2014;57(Suppl 1):S7
   Google Scholar
• Goossen K, Graber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2012;14(12):1061-72
   PubMed Web of Science ®Google Scholar
• Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014;103(3):373-81
   PubMed Web of Science ®Google Scholar
• Leiter LA, Cefalu WT, de Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014;62(7):1252-62
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382(9896):941-50
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369(14):1317-26
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR - TIMI 53 randomized trial. Circulation 2014;130(18):1579-88
   PubMed Web of Science ®Google Scholar
• Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab 2013;15(4):291-300
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014;37(Suppl 1):S14-80
   PubMed Web of Science ®Google Scholar
• Garcia-Perez LE, Alvarez M, Dilla T, et al. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4(2):175-94
   PubMed Web of Science ®Google Scholar
• Vittorino Gaddi A, Benedetto D, Capello F, et al. Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens. Public Health 2014;128(1):70-6
   PubMedGoogle Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19(2):327-36
   PubMed Web of Science ®Google Scholar
• Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014;13:102
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Buse JB, Del Prato S, et al. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors’ expert forum. Diabetes Care 2014;37(9):2647-59
   PubMedGoogle Scholar
• Colombo GL, Rossi E, De Rosa M, et al. Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence 2012;6:653-61
   PubMed Web of Science ®Google Scholar
• Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008;30(10):1893-907
   PubMed Web of Science ®Google Scholar
• Wertheimer AI. The economics of polypharmacology: fixed dose combinations and drug cocktails. Curr Med Chem 2013;20(13):1635-8
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Tradjenta (linagliptin) prescribing information. Available from: www.tradjenta.com/
   Google Scholar
• Boehringer Ingelheim. Trajenta (linagliptin) summary of product characteristics. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002110/WC500115745.pdf
   Google Scholar
• Bristol-Myers Squibb, AstraZeneca. Onglyza (saxagliptin) prescribing information. Available from: www.onglyza-hcp.com/hcp/hcp.aspx
   Google Scholar
• Merck & Co. Januvia (sitagliptin) prescribing information. Available from: www.januvia.com/sitagliptin/januvia/consumer/prescribing-information.jsp
   Google Scholar
• Boehringer Ingelheim. Jardiance® (empagliflozin) prescribing information. Available from: www.jardiance.com/
   Google Scholar
• Bristol-Myers Squibb, AstraZeneca. Farxiga (dapagliflozin) prescribing information. Available from: www.farxiga.com/
   Google Scholar
• Janssen Pharmaceuticals. Invokana (canagliflozin) prescribing information. Available from: www.invokanahcp.com/dosing-and-prescribing-information
   Google Scholar
• Safety and efficacy of the combination of empagliflozin and linagliptin compared to linagliptin alone over 24 weeks in patients with type 2 diabetes. Available from: https://clinicaltrials.gov/ct2/show/NCT01734785
   Google Scholar
• Linagliptin as add on therapy to empagliflozin 10 mg or 25 mg with background metformin in patient with type 2 diabetes. Available from: https://clinicaltrials.gov/ct2/show/NCT01778049
   Google Scholar
• Safety and efficacy of dapagliflozin in triple therapy to treat subjects with type 2 diabetes. Available from: https://clinicaltrials.gov/ct2/show/NCT01646320
   Google Scholar
• Safety and efficacy of saxagliptin in triple therapy to treat subjects with type 2 diabetes. Available from: https://clinicaltrials.gov/ct2/show/NCT01619059
   Google Scholar
• A study to evaluate the efficacy and safety of the addition of canagliflozin in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin and sitagliptin. Available from: https://clinicaltrials.gov/ct2/show/NCT02025907
   Google Scholar
• Drucker DJ. The Biology of incretin hormones. Cell Metab 2006;3(3):153-65
   PubMed Web of Science ®Google Scholar